絞り込み

16426

広告

奄美ノネコ捕獲計画案、1週間期限譲渡先探す - 読売新聞

読売新聞奄美ノネコ捕獲計画案、1週間期限譲渡先探す読売新聞世界自然遺産登録を目指す奄美大島で野生化したネコ(ノネコ)が固有種を襲っている問題で、環境省と鹿児島県...

  1. 福島第1、屋根カバー設置を完了 (デイリ...
  2. Tesla、パブリッククラウド環境に不正...
  3. どうなる、地球温暖化時代の「冬季五輪」 ...
  4. [企業] Ionis 腎疾患治療アンチセ...

ニュース一覧

Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis.

著者 Iwakiri K
J Nippon Med Sch.2017 ; 84(5):209-214.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (64view , 0users)

Full Text Sources

Reflux esophagitis is characterized by excessive esophageal acid exposure. To treat reflux esophagitis, it is necessary to reduce excessive esophageal acid exposure to within the normal range. The first-line drug for the treatment of reflux esophagitis is a standard-dose proton-pump inhibitor (PPI), which is also recommended by the Evidence-based Clinical Practice Guidelines 2015 for gastroesophageal disease of the Japanese Society of Gastroenterology. It has been reported that the response to a standard dose of PPI in patients with mild reflux esophagitis is 90-100%, and that in patients with severe reflux esophagitis is 80-85%. However, PPI-resistant reflux esophagitis has been increasing. When the standard dose of PPI is not effective, modification of the lifestyle with PPI therapy, switching to another PPI, or a change in the administration method (before meals), as well as double-dose PPI (in divided doses), may be effective. In addition, vonoprazan (potassium-competitive acid blocker), which has rapid and potent acid-suppressive effects, became available in February 2015 in Japan. In the clinical trial data, vonoprazan is very effective for reflux esophagitis. However, clinical data on vonoprazan are still insufficient. The establishment of a new treatment for reflux esophagitis taking advantage of the rapid and potent acid-suppressive effects is awaited.
PMID: 29142181 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード